| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 41 | 2024 | 4140 | 4.270 |
Why?
|
| Metformin | 13 | 2024 | 393 | 3.260 |
Why?
|
| Carcinoma, Squamous Cell | 43 | 2024 | 5591 | 3.170 |
Why?
|
| Papillomavirus Infections | 14 | 2024 | 999 | 2.750 |
Why?
|
| Esophageal Neoplasms | 29 | 2018 | 3240 | 1.670 |
Why?
|
| Radiation Tolerance | 15 | 2023 | 637 | 1.660 |
Why?
|
| Hypoglycemic Agents | 7 | 2021 | 598 | 1.460 |
Why?
|
| Chemoradiotherapy | 20 | 2024 | 2027 | 1.230 |
Why?
|
| Oropharyngeal Neoplasms | 14 | 2022 | 1161 | 1.230 |
Why?
|
| Papillomaviridae | 9 | 2022 | 636 | 1.180 |
Why?
|
| Adenocarcinoma | 20 | 2018 | 7915 | 1.020 |
Why?
|
| Homologous Recombination | 2 | 2021 | 187 | 0.860 |
Why?
|
| Tumor Suppressor Protein p53 | 12 | 2024 | 3656 | 0.810 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2022 | 506 | 0.800 |
Why?
|
| Cell Line, Tumor | 33 | 2024 | 14838 | 0.780 |
Why?
|
| CREB-Binding Protein | 1 | 2021 | 98 | 0.760 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2021 | 97 | 0.760 |
Why?
|
| Radiotherapy, Intensity-Modulated | 12 | 2023 | 2161 | 0.740 |
Why?
|
| Neoplasm Recurrence, Local | 20 | 2024 | 10385 | 0.740 |
Why?
|
| Gain of Function Mutation | 1 | 2021 | 133 | 0.720 |
Why?
|
| Radiation-Sensitizing Agents | 3 | 2020 | 366 | 0.710 |
Why?
|
| Histone Acetyltransferases | 1 | 2021 | 433 | 0.670 |
Why?
|
| Biomarkers, Tumor | 16 | 2023 | 10706 | 0.660 |
Why?
|
| Laryngeal Neoplasms | 6 | 2020 | 529 | 0.650 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2020 | 271 | 0.620 |
Why?
|
| Cisplatin | 8 | 2024 | 2496 | 0.610 |
Why?
|
| Indazoles | 1 | 2020 | 310 | 0.600 |
Why?
|
| DNA Damage | 4 | 2022 | 1988 | 0.600 |
Why?
|
| Humans | 129 | 2024 | 270802 | 0.590 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2017 | 1710 | 0.560 |
Why?
|
| Nelfinavir | 1 | 2016 | 16 | 0.540 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2017 | 225 | 0.530 |
Why?
|
| Rectal Neoplasms | 2 | 2016 | 1240 | 0.530 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2024 | 5569 | 0.530 |
Why?
|
| Neoplasm Staging | 18 | 2024 | 14012 | 0.520 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2021 | 3919 | 0.510 |
Why?
|
| Malate Dehydrogenase | 1 | 2015 | 20 | 0.510 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2016 | 116 | 0.510 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2022 | 875 | 0.510 |
Why?
|
| Cellular Senescence | 2 | 2015 | 389 | 0.510 |
Why?
|
| Esophagectomy | 10 | 2017 | 946 | 0.500 |
Why?
|
| Glucose | 2 | 2023 | 1220 | 0.490 |
Why?
|
| Antineoplastic Agents | 13 | 2023 | 14616 | 0.480 |
Why?
|
| Signal Transduction | 10 | 2022 | 12102 | 0.480 |
Why?
|
| Lung Neoplasms | 8 | 2024 | 12028 | 0.480 |
Why?
|
| Middle Aged | 67 | 2024 | 90347 | 0.470 |
Why?
|
| Radiosurgery | 2 | 2024 | 1383 | 0.470 |
Why?
|
| Salvage Therapy | 8 | 2019 | 2122 | 0.470 |
Why?
|
| Chemoradiotherapy, Adjuvant | 7 | 2017 | 562 | 0.470 |
Why?
|
| Piperidines | 1 | 2020 | 1098 | 0.460 |
Why?
|
| Furans | 1 | 2014 | 102 | 0.460 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2004 | 135 | 0.450 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2022 | 1902 | 0.450 |
Why?
|
| Male | 75 | 2024 | 128397 | 0.440 |
Why?
|
| Aged | 58 | 2024 | 73382 | 0.440 |
Why?
|
| MicroRNAs | 2 | 2018 | 2886 | 0.440 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 678 | 0.430 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2017 | 2618 | 0.420 |
Why?
|
| Proteomics | 3 | 2017 | 1427 | 0.420 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2014 | 351 | 0.410 |
Why?
|
| Mouth Neoplasms | 4 | 2020 | 734 | 0.410 |
Why?
|
| Carrier Proteins | 2 | 2022 | 2100 | 0.410 |
Why?
|
| Retrospective Studies | 43 | 2024 | 39832 | 0.410 |
Why?
|
| Proteome | 1 | 2016 | 571 | 0.400 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 5 | 2018 | 281 | 0.400 |
Why?
|
| Esophagogastric Junction | 4 | 2017 | 557 | 0.390 |
Why?
|
| Protein Conformation | 1 | 2014 | 1255 | 0.380 |
Why?
|
| Female | 68 | 2024 | 148967 | 0.380 |
Why?
|
| Diabetes Complications | 1 | 2012 | 303 | 0.360 |
Why?
|
| Diabetes Mellitus | 3 | 2015 | 1042 | 0.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2020 | 9041 | 0.350 |
Why?
|
| B7-H1 Antigen | 1 | 2017 | 1089 | 0.350 |
Why?
|
| Treatment Outcome | 26 | 2024 | 33741 | 0.350 |
Why?
|
| Apoptosis | 8 | 2024 | 7754 | 0.330 |
Why?
|
| Patient Reported Outcome Measures | 5 | 2024 | 864 | 0.330 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2011 | 144 | 0.330 |
Why?
|
| Radiometry | 3 | 2017 | 1018 | 0.320 |
Why?
|
| Combined Modality Therapy | 17 | 2020 | 9039 | 0.320 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2011 | 2175 | 0.310 |
Why?
|
| Eye Neoplasms | 1 | 2011 | 257 | 0.310 |
Why?
|
| Thyroid Neoplasms | 5 | 2018 | 1884 | 0.300 |
Why?
|
| Disease-Free Survival | 17 | 2020 | 10260 | 0.300 |
Why?
|
| Aged, 80 and over | 27 | 2020 | 31008 | 0.300 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2018 | 3408 | 0.300 |
Why?
|
| Checkpoint Kinase 1 | 2 | 2020 | 169 | 0.290 |
Why?
|
| Adult | 45 | 2024 | 81997 | 0.290 |
Why?
|
| Prognosis | 21 | 2024 | 22481 | 0.280 |
Why?
|
| Positron-Emission Tomography | 6 | 2020 | 2196 | 0.280 |
Why?
|
| Neoplasm Metastasis | 7 | 2018 | 5310 | 0.270 |
Why?
|
| Dose-Response Relationship, Radiation | 4 | 2017 | 751 | 0.270 |
Why?
|
| Mastectomy | 1 | 2013 | 1553 | 0.270 |
Why?
|
| Liver Neoplasms | 3 | 2014 | 4820 | 0.260 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 1032 | 0.260 |
Why?
|
| Transcription Factors | 6 | 2018 | 5440 | 0.260 |
Why?
|
| Induction Chemotherapy | 3 | 2018 | 670 | 0.260 |
Why?
|
| ErbB Receptors | 1 | 2014 | 2376 | 0.260 |
Why?
|
| Cetuximab | 3 | 2017 | 474 | 0.260 |
Why?
|
| Lymph Nodes | 4 | 2020 | 3078 | 0.260 |
Why?
|
| Survival Rate | 14 | 2024 | 12527 | 0.250 |
Why?
|
| Reactive Oxygen Species | 4 | 2015 | 1006 | 0.250 |
Why?
|
| Aging | 2 | 2011 | 1550 | 0.250 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2024 | 7784 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2018 | 16669 | 0.250 |
Why?
|
| Mice | 15 | 2021 | 35597 | 0.250 |
Why?
|
| Cancer Survivors | 3 | 2024 | 744 | 0.250 |
Why?
|
| Animals | 22 | 2021 | 62048 | 0.240 |
Why?
|
| Mice, Nude | 8 | 2021 | 4329 | 0.240 |
Why?
|
| Lactic Acid | 2 | 2017 | 310 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2024 | 5403 | 0.230 |
Why?
|
| Survival Analysis | 11 | 2020 | 9290 | 0.230 |
Why?
|
| Arsenites | 1 | 2004 | 20 | 0.230 |
Why?
|
| Radiotherapy Dosage | 6 | 2023 | 4001 | 0.230 |
Why?
|
| Teratogens | 1 | 2004 | 92 | 0.220 |
Why?
|
| Mutation | 9 | 2022 | 15911 | 0.220 |
Why?
|
| Veterans | 4 | 2019 | 1740 | 0.220 |
Why?
|
| Neoadjuvant Therapy | 7 | 2018 | 5231 | 0.220 |
Why?
|
| Risk Assessment | 8 | 2019 | 6768 | 0.220 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2004 | 79 | 0.220 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2018 | 1469 | 0.210 |
Why?
|
| Neoplasms | 6 | 2023 | 15919 | 0.210 |
Why?
|
| Pyrimidinones | 3 | 2020 | 318 | 0.210 |
Why?
|
| Fluorouracil | 6 | 2017 | 1989 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1417 | 0.200 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 1903 | 0.200 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2022 | 40 | 0.200 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2018 | 1260 | 0.200 |
Why?
|
| Margins of Excision | 2 | 2024 | 315 | 0.200 |
Why?
|
| Glottis | 2 | 2019 | 68 | 0.200 |
Why?
|
| Prospective Studies | 11 | 2024 | 13417 | 0.190 |
Why?
|
| Follow-Up Studies | 12 | 2020 | 15212 | 0.190 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 5002 | 0.190 |
Why?
|
| Deglutition Disorders | 3 | 2024 | 489 | 0.190 |
Why?
|
| Lymphedema | 1 | 2024 | 239 | 0.180 |
Why?
|
| Pyrazoles | 3 | 2020 | 1544 | 0.180 |
Why?
|
| Gene Expression | 4 | 2018 | 3642 | 0.180 |
Why?
|
| Caspase 8 | 1 | 2020 | 146 | 0.180 |
Why?
|
| Histones | 3 | 2017 | 1512 | 0.180 |
Why?
|
| Transcriptional Activation | 1 | 2004 | 1111 | 0.180 |
Why?
|
| Acetylation | 1 | 2021 | 514 | 0.180 |
Why?
|
| Radiation, Ionizing | 3 | 2015 | 190 | 0.180 |
Why?
|
| Protein Domains | 1 | 2021 | 323 | 0.180 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2020 | 1838 | 0.170 |
Why?
|
| Ubiquitin | 1 | 2022 | 331 | 0.170 |
Why?
|
| DNA, Viral | 1 | 2022 | 756 | 0.170 |
Why?
|
| Disease Models, Animal | 6 | 2021 | 7383 | 0.170 |
Why?
|
| Conservative Treatment | 1 | 2019 | 65 | 0.160 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 3439 | 0.160 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 57 | 0.160 |
Why?
|
| Quality of Life | 3 | 2024 | 4775 | 0.160 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2019 | 38 | 0.160 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2019 | 62 | 0.160 |
Why?
|
| Single-Blind Method | 1 | 2020 | 416 | 0.160 |
Why?
|
| Cell Cycle Proteins | 2 | 2020 | 2115 | 0.160 |
Why?
|
| Neoplastic Stem Cells | 3 | 2018 | 1457 | 0.160 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2024 | 417 | 0.160 |
Why?
|
| Cell Survival | 3 | 2014 | 3063 | 0.160 |
Why?
|
| Young Adult | 13 | 2019 | 22225 | 0.160 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 271 | 0.160 |
Why?
|
| Pyrimidines | 4 | 2020 | 3667 | 0.160 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 4328 | 0.160 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 526 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2017 | 6255 | 0.150 |
Why?
|
| Urination Disorders | 1 | 2018 | 63 | 0.150 |
Why?
|
| Diagnostic Imaging | 2 | 2019 | 1174 | 0.150 |
Why?
|
| Rectal Diseases | 1 | 2018 | 57 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2018 | 880 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 1579 | 0.150 |
Why?
|
| Radiation Oncology | 1 | 2023 | 558 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2018 | 135 | 0.150 |
Why?
|
| Lymphatic Metastasis | 6 | 2019 | 4963 | 0.150 |
Why?
|
| Treatment Failure | 4 | 2016 | 1428 | 0.150 |
Why?
|
| Radiation Injuries | 4 | 2018 | 1470 | 0.150 |
Why?
|
| Radiotherapy | 3 | 2014 | 1857 | 0.150 |
Why?
|
| Linear Models | 3 | 2019 | 1097 | 0.150 |
Why?
|
| Minority Groups | 1 | 2020 | 328 | 0.150 |
Why?
|
| Lymphopenia | 1 | 2020 | 211 | 0.150 |
Why?
|
| Surgical Oncology | 1 | 2020 | 211 | 0.140 |
Why?
|
| Neoplasm, Residual | 2 | 2015 | 1752 | 0.140 |
Why?
|
| Organ Transplantation | 1 | 2020 | 203 | 0.140 |
Why?
|
| Transplant Recipients | 1 | 2020 | 336 | 0.140 |
Why?
|
| Laryngectomy | 2 | 2016 | 243 | 0.140 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2017 | 115 | 0.140 |
Why?
|
| Genomics | 3 | 2019 | 2836 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 1655 | 0.140 |
Why?
|
| Transfection | 3 | 2017 | 3118 | 0.140 |
Why?
|
| Mitochondria | 4 | 2020 | 1299 | 0.140 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2023 | 2450 | 0.140 |
Why?
|
| Survivors | 2 | 2019 | 1023 | 0.140 |
Why?
|
| Cell Proliferation | 8 | 2017 | 7237 | 0.130 |
Why?
|
| Risk Factors | 8 | 2024 | 17900 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2018 | 478 | 0.130 |
Why?
|
| Glycolysis | 3 | 2014 | 530 | 0.130 |
Why?
|
| Proportional Hazards Models | 8 | 2017 | 5102 | 0.130 |
Why?
|
| Skull Base | 1 | 2017 | 225 | 0.130 |
Why?
|
| Immunoblotting | 2 | 2014 | 895 | 0.130 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2018 | 199 | 0.130 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2016 | 327 | 0.130 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 3031 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 2 | 2015 | 1077 | 0.130 |
Why?
|
| Proton Therapy | 3 | 2017 | 1635 | 0.130 |
Why?
|
| Serous Membrane | 1 | 2015 | 9 | 0.130 |
Why?
|
| Cohort Studies | 7 | 2019 | 9474 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2019 | 646 | 0.130 |
Why?
|
| Medical Oncology | 2 | 2023 | 1465 | 0.120 |
Why?
|
| Phosphoproteins | 2 | 2017 | 1137 | 0.120 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 518 | 0.120 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2015 | 123 | 0.120 |
Why?
|
| Tumor Burden | 3 | 2017 | 2033 | 0.120 |
Why?
|
| Deoxyglucose | 2 | 2012 | 122 | 0.120 |
Why?
|
| Betacoronavirus | 1 | 2020 | 513 | 0.120 |
Why?
|
| Ubiquitination | 1 | 2017 | 579 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2019 | 1689 | 0.120 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2014 | 88 | 0.120 |
Why?
|
| Radiation | 1 | 2014 | 19 | 0.120 |
Why?
|
| Random Allocation | 1 | 2016 | 741 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2017 | 288 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2020 | 822 | 0.120 |
Why?
|
| Multimodal Imaging | 2 | 2015 | 550 | 0.120 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2015 | 123 | 0.120 |
Why?
|
| Texas | 6 | 2020 | 6447 | 0.120 |
Why?
|
| Prostatic Neoplasms | 4 | 2018 | 5860 | 0.120 |
Why?
|
| Stomach Neoplasms | 2 | 2017 | 2330 | 0.120 |
Why?
|
| beta-Galactosidase | 1 | 2014 | 274 | 0.120 |
Why?
|
| Blotting, Western | 4 | 2015 | 3588 | 0.110 |
Why?
|
| Mucous Membrane | 1 | 2015 | 263 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2007 | 396 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 537 | 0.110 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2015 | 288 | 0.110 |
Why?
|
| Aniline Compounds | 1 | 2015 | 206 | 0.110 |
Why?
|
| Disease Management | 1 | 2019 | 1089 | 0.110 |
Why?
|
| Protein Multimerization | 1 | 2014 | 232 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 637 | 0.110 |
Why?
|
| Smoking | 4 | 2015 | 2555 | 0.110 |
Why?
|
| Retinal Dehydrogenase | 1 | 2013 | 85 | 0.110 |
Why?
|
| Cancer Care Facilities | 3 | 2017 | 907 | 0.110 |
Why?
|
| Bilirubin | 1 | 2014 | 226 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2020 | 1280 | 0.110 |
Why?
|
| Skull Base Neoplasms | 1 | 2017 | 339 | 0.110 |
Why?
|
| Telemedicine | 1 | 2020 | 552 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2014 | 1564 | 0.110 |
Why?
|
| Gene Dosage | 1 | 2016 | 823 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2014 | 1121 | 0.110 |
Why?
|
| Body Composition | 1 | 2016 | 607 | 0.110 |
Why?
|
| Carbon Isotopes | 1 | 2014 | 364 | 0.110 |
Why?
|
| Tongue Neoplasms | 1 | 2015 | 253 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 327 | 0.100 |
Why?
|
| Radiation Pneumonitis | 1 | 2015 | 313 | 0.100 |
Why?
|
| Pyruvic Acid | 1 | 2014 | 132 | 0.100 |
Why?
|
| Vaginal Neoplasms | 1 | 2013 | 152 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 625 | 0.100 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2013 | 201 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 700 | 0.100 |
Why?
|
| United States | 5 | 2019 | 15855 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 5 | 2024 | 4048 | 0.100 |
Why?
|
| DNA Repair | 1 | 2020 | 1910 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 2017 | 1712 | 0.100 |
Why?
|
| Ions | 1 | 2011 | 56 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2005 | 263 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2017 | 6398 | 0.100 |
Why?
|
| Vulvar Neoplasms | 1 | 2013 | 235 | 0.100 |
Why?
|
| Penile Neoplasms | 1 | 2013 | 183 | 0.100 |
Why?
|
| Cell Death | 1 | 2014 | 686 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2014 | 402 | 0.090 |
Why?
|
| Isoenzymes | 1 | 2013 | 651 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 1335 | 0.090 |
Why?
|
| Pandemics | 1 | 2020 | 1610 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 7895 | 0.090 |
Why?
|
| Carbon | 1 | 2011 | 165 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 3 | 2014 | 5759 | 0.090 |
Why?
|
| Mutant Proteins | 1 | 2011 | 234 | 0.090 |
Why?
|
| Radiographic Image Enhancement | 1 | 2013 | 410 | 0.090 |
Why?
|
| Esophagus | 1 | 2013 | 563 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 1401 | 0.090 |
Why?
|
| Incidence | 3 | 2019 | 5828 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2015 | 2091 | 0.090 |
Why?
|
| Sirolimus | 2 | 2004 | 831 | 0.080 |
Why?
|
| Patient Selection | 1 | 2017 | 2026 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 1189 | 0.080 |
Why?
|
| Ovarian Neoplasms | 2 | 2007 | 4795 | 0.080 |
Why?
|
| Anus Neoplasms | 1 | 2013 | 414 | 0.080 |
Why?
|
| Organs at Risk | 2 | 2023 | 559 | 0.080 |
Why?
|
| Pharynx | 2 | 2020 | 150 | 0.080 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 1341 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 1292 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 16205 | 0.080 |
Why?
|
| Particle Accelerators | 1 | 2011 | 362 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1335 | 0.080 |
Why?
|
| Survivorship | 2 | 2020 | 116 | 0.080 |
Why?
|
| Enzyme Activation | 3 | 2014 | 1811 | 0.080 |
Why?
|
| Energy Metabolism | 1 | 2014 | 998 | 0.080 |
Why?
|
| Chromones | 2 | 2006 | 121 | 0.080 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 2 | 2007 | 13 | 0.080 |
Why?
|
| Phosphorylation | 3 | 2006 | 4943 | 0.070 |
Why?
|
| Prevalence | 2 | 2013 | 3402 | 0.070 |
Why?
|
| Drug Synergism | 3 | 2015 | 1359 | 0.070 |
Why?
|
| Taxoids | 3 | 2016 | 1015 | 0.070 |
Why?
|
| Databases, Genetic | 2 | 2020 | 757 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2017 | 4117 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 5149 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 4961 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 4498 | 0.070 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 681 | 0.070 |
Why?
|
| Morpholines | 2 | 2006 | 296 | 0.070 |
Why?
|
| Visual Acuity | 1 | 2011 | 862 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2015 | 1933 | 0.070 |
Why?
|
| Leptin | 2 | 2006 | 306 | 0.070 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2005 | 10 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 266 | 0.060 |
Why?
|
| Caspases | 2 | 2020 | 679 | 0.060 |
Why?
|
| Reflex, Startle | 1 | 2005 | 66 | 0.060 |
Why?
|
| Neck Dissection | 2 | 2019 | 294 | 0.060 |
Why?
|
| Platinum Compounds | 2 | 2017 | 129 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 5778 | 0.060 |
Why?
|
| Receptors, Cell Surface | 2 | 2006 | 904 | 0.060 |
Why?
|
| Genes, p53 | 2 | 2022 | 1140 | 0.060 |
Why?
|
| Remission Induction | 3 | 2017 | 3652 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2004 | 60 | 0.060 |
Why?
|
| Inflammation | 1 | 2014 | 2518 | 0.060 |
Why?
|
| Mitochondrial Proteins | 2 | 2020 | 380 | 0.060 |
Why?
|
| Carcinoma | 1 | 2015 | 2609 | 0.060 |
Why?
|
| Bridged-Ring Compounds | 2 | 2015 | 190 | 0.060 |
Why?
|
| Nomograms | 2 | 2016 | 312 | 0.060 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2024 | 202 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 6193 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 4892 | 0.050 |
Why?
|
| Organoplatinum Compounds | 2 | 2016 | 704 | 0.050 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2023 | 118 | 0.050 |
Why?
|
| DNA Copy Number Variations | 2 | 2020 | 1568 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 4645 | 0.050 |
Why?
|
| Hospitals, Veterans | 2 | 2015 | 371 | 0.050 |
Why?
|
| Fear | 1 | 2003 | 259 | 0.050 |
Why?
|
| Heterografts | 2 | 2014 | 739 | 0.050 |
Why?
|
| Neck | 1 | 2024 | 395 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2004 | 526 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 256 | 0.050 |
Why?
|
| Caspase Inhibitors | 1 | 2020 | 95 | 0.050 |
Why?
|
| Biomimetics | 1 | 2020 | 37 | 0.050 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 4958 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2016 | 1042 | 0.040 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2020 | 25 | 0.040 |
Why?
|
| Pennsylvania | 1 | 2020 | 68 | 0.040 |
Why?
|
| Dipeptides | 1 | 2020 | 96 | 0.040 |
Why?
|
| Radiography | 2 | 2016 | 1988 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 2271 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2003 | 493 | 0.040 |
Why?
|
| Protein Binding | 2 | 2018 | 3485 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2004 | 903 | 0.040 |
Why?
|
| Biomarkers | 2 | 2023 | 5060 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 5255 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2019 | 237 | 0.040 |
Why?
|
| DNA, Mitochondrial | 1 | 2020 | 315 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2019 | 354 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 400 | 0.040 |
Why?
|
| Early Detection of Cancer | 2 | 2019 | 1340 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 749 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2018 | 269 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2018 | 164 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 622 | 0.040 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 219 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2019 | 250 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 1097 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2014 | 3045 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 4001 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 279 | 0.040 |
Why?
|
| Gastrostomy | 1 | 2019 | 196 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 547 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2019 | 6237 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2004 | 2073 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 283 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 254 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2018 | 820 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 897 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 307 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2017 | 234 | 0.030 |
Why?
|
| G2 Phase | 1 | 2016 | 218 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2020 | 619 | 0.030 |
Why?
|
| Zebrafish | 1 | 2019 | 457 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 729 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 4963 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling 3 Protein | 2 | 2006 | 24 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2016 | 179 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 272 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 521 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2019 | 1685 | 0.030 |
Why?
|
| Hospitals, Military | 1 | 2015 | 12 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2015 | 78 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 7665 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 2 | 2006 | 62 | 0.030 |
Why?
|
| Receptors, Leptin | 2 | 2006 | 67 | 0.030 |
Why?
|
| Indoles | 1 | 2020 | 1028 | 0.030 |
Why?
|
| Capecitabine | 1 | 2016 | 390 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2019 | 585 | 0.030 |
Why?
|
| Mucositis | 1 | 2015 | 149 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 285 | 0.030 |
Why?
|
| Stomatitis | 1 | 2016 | 193 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2017 | 453 | 0.030 |
Why?
|
| Gene Editing | 1 | 2017 | 229 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 398 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2019 | 1825 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2020 | 1275 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2019 | 1462 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2017 | 440 | 0.030 |
Why?
|
| Ribosomal Protein S6 | 1 | 2014 | 46 | 0.030 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2014 | 52 | 0.030 |
Why?
|
| SOX9 Transcription Factor | 1 | 2015 | 178 | 0.030 |
Why?
|
| Fluoresceins | 1 | 2014 | 74 | 0.030 |
Why?
|
| Carcinogens | 1 | 2015 | 391 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2022 | 1208 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 362 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2020 | 1033 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 908 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 728 | 0.030 |
Why?
|
| Repressor Proteins | 2 | 2016 | 1717 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2014 | 220 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 659 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2015 | 255 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 1822 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2018 | 2137 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 5071 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 1320 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 737 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 445 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 2013 | 128 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 1293 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2013 | 347 | 0.030 |
Why?
|
| Adolescent | 3 | 2019 | 32743 | 0.030 |
Why?
|
| Cell Separation | 1 | 2014 | 610 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2016 | 967 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2006 | 669 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 2251 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 880 | 0.030 |
Why?
|
| Alcoholism | 1 | 2015 | 330 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 704 | 0.030 |
Why?
|
| Weight Loss | 1 | 2016 | 629 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2014 | 1054 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 566 | 0.020 |
Why?
|
| Rectum | 1 | 2014 | 480 | 0.020 |
Why?
|
| Cesium Radioisotopes | 1 | 2011 | 38 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 5923 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2015 | 2320 | 0.020 |
Why?
|
| Cognition | 1 | 2017 | 969 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 600 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2014 | 593 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2014 | 607 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 324 | 0.020 |
Why?
|
| Diet | 1 | 2019 | 1480 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 1554 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2016 | 898 | 0.020 |
Why?
|
| Metabolomics | 1 | 2014 | 504 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 1099 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 3194 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 419 | 0.020 |
Why?
|
| Decision Making | 1 | 2017 | 1251 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 1387 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 1940 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 4223 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 3448 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2005 | 2212 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 5731 | 0.020 |
Why?
|
| Reoperation | 1 | 2013 | 1392 | 0.020 |
Why?
|
| Mass Screening | 1 | 2017 | 1549 | 0.020 |
Why?
|
| Prostate | 1 | 2014 | 1089 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2016 | 2238 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 2196 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 2209 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 1347 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 4375 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 2472 | 0.020 |
Why?
|
| Time Factors | 2 | 2013 | 13021 | 0.020 |
Why?
|
| Butadienes | 1 | 2006 | 36 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2014 | 2165 | 0.020 |
Why?
|
| Luciferases | 1 | 2007 | 460 | 0.020 |
Why?
|
| Transcriptome | 1 | 2015 | 1960 | 0.020 |
Why?
|
| Radioligand Assay | 1 | 2005 | 57 | 0.020 |
Why?
|
| Tritium | 1 | 2005 | 268 | 0.020 |
Why?
|
| Rats | 2 | 2005 | 6525 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2005 | 329 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 2005 | 121 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 6855 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 5171 | 0.010 |
Why?
|
| Corticosterone | 1 | 2003 | 123 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 2399 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2003 | 168 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2004 | 848 | 0.010 |
Why?
|
| Nitriles | 1 | 2006 | 939 | 0.010 |
Why?
|
| Pregnancy | 2 | 2005 | 8125 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2003 | 501 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 2657 | 0.010 |
Why?
|
| Hippocampus | 1 | 2005 | 973 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2003 | 1372 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 1946 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 2003 | 563 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 3532 | 0.010 |
Why?
|
| Pyridines | 1 | 2005 | 1311 | 0.010 |
Why?
|
| Piperazines | 1 | 2005 | 2145 | 0.010 |
Why?
|